Patients requiring urgent surgical revascularization due to unstable coronary artery disease are usually pretreated with multiple antithrombotic drugs. The perioperative risks of this type of treatment were investigated in 123 patients who underwent emergency coronary artery bypass grafting (CABG) at our institution.
Eighty-two patients (group A) received heparin and acetylsalicylic acid solely and 41 patients (group B) received additionally ADP-receptor antagonists (82.9%), glycoprotein IIb/IIIa inhibitors (12.2%) or thrombolysis (14.6%) preoperatively. Both groups were similar regarding demographic data and overall clinical status. Preoperative coagulation parameters and intraoperative characteristics were comparable. Blood loss via chest tubes was not significantly different between groups. Transfusion of red blood cells and fresh frozen plasma were slightly, but not significantly increased in group B. Transfusion of pooled platelets was low in general and similar in both groups. Re-exploration rate, medium intensive care unit and hospital stay as well as perioperative mortality were comparable.
Excessive antithrombotic pretreatment seems to bear no additional risk in emergency CABG and may be beneficial in this setting.
SerruysP. W., De JaegereP., KiemeneijF., (for the Benestent Study Group). A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. New England Journal of Medicine, 1994, 331, 489–495.
2.
FavaloroR. G., Landmarks in the development of coronary artery bypass surgery. Circulation, 1998, 98, 466–478.
3.
AndersonH. V., CannonC. P., StoneP. H., One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. Journal of the American College of Cardiology, 1995, 26, 1643–1650.
4.
YusufS., ZuckerD., PeduzziP., Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet, 1994, 344, 563–570.
5.
WallentinL., LagerqvistB., HustedS., Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast revascularisation during instability in coronary artery disease. Lancet, 2000, 356, 9–16.
6.
MoosviA. R., KhajaF., VillanuevaL., Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. Journal of the American College of Cardiology, 1992, 19, 907–914.
7.
HochmanJ. S., SleeperL. A., WebbJ. G., Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. New England Journal of Medicine, 1999, 341, 625–634.
8.
EPISTENT Investigators, Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet, 1998, 352, 87–92.
9.
CalafioreA. M., TeodoriG., MezzettiA., Intermittent antegrade warm blood cardioplegia. Annals of Thoracic Surgery, 1995, 59, 398–102.
10.
BistrupB. P., RoystonD., SapsfordR. N., Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). Journal of Thoracic and Cardiovascular Surgery, 1989, 97, 364–372.
11.
DietrichW., SpannaglW., JochumM., Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology, 1990, 73, 1119–1126.
12.
MurakamiT., FujiwaraT., FukuhiroY., Long-term results of emergency coronary artery bypass grafting. Japanese Heart Journal, 1996, 37, 447–453.
13.
CraverJ. M., JusticzA. G., WeintraubW. S., Coronary artery bypass grafting in patients after failure of intracoronary stenting. Annals of Thoracic Surgery, 1996, 61, 27–32.
14.
NollertG., AmendJ., DetterC., Coronary artery bypass grafting after failed coronary angioplasty: risk factors and long-term results. Thoracic and Cardiovascular Surgery, 1995, 43, 35–39.
15.
ReberD., SendtnerE., TollenaereP., Emergency coronary artery bypass grafting after failed percutaneous transluminal angioplasty versus elective bypass grafting. Journal of Cardiovascular Surgery, 1996, 37(Suppl. 1), 71–73.
16.
SimicO., MaringJ., SteinJ., Emergency coronary artery bypass grafting following failed percutaneous coronary angioplasty — early and late results after operation. Zentralbl. Chirurgie, 1997, 122, 149–152.
17.
LazarH. L., JacobsA. K., AldeaG. S., Factors influencing mortality after emergency coronary artery bypass grafting for failed percutaneous transluminal coronary angioplasty. Annals of Thoracic Surgery, 1997, 64, 1747–1752.
18.
AntmanE. M., GiuglianoR. P., GibsonC. M., Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 Trial. Circulation, 1999, 99, 2720–2732.
19.
SethiG. K., CopelandJ. G., GoldmanS., Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. Journal of the American College of Cardiology, 1990, 15, 15–20.
20.
FerrarisV. A., FerrarisS. P., LoughF. C., Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Annals of Thoracic Surgery, 1995, 59, 1036–1037.
21.
GammieJ. S., ZenatiM., KormosR. L., Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Annals of Thoracic Surgery, 1998, 65, 465–469.
22.
JuergensC. P., YeungA. C. and OesterleS. N., Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. American Journal of Cardiology, 1997, 80, 74–75.
23.
ArjomandH., MascarenhasD. A. and MorganR. J., Abciximab and the risk of bleeding during emergency cardiac operations. Annals of Thoracic Surgery, 1999, 67, 292–293.
24.
DykeC. M., Safety of glycoprotein IIb-IIIa inhibitors: a heart surgeon's perspective. American Heart Journal, 1999, 138, 307–316.
25.
KurkiT. S. O. and KatajaM., Preoperative prediction of post-operative morbidity in coronary artery bypass grafting. Annals of Thoracic Surgery, 1996, 61, 1740–1745.
